This Week in HIV Research: The Perils of Polypharmacy

This Week in HIV Research: The Perils of Polypharmacy

1 of 5
Next >

In our latest brief set of recaps from the world of recently published HIV research, we learn about studies that suggest:

  • Polypharmacy doesn't appear much riskier for people with HIV than people without -- but it's still a health risk factor, and an awfully common one at that.
  • In certain cases, PrEP use may well be associated with higher sexually transmitted infection incidence among MSM.
  • Particular species of vaginal bacteria may be associated with a greater risk of HIV seroconversion following a viral exposure.
  • Early initiation of HIV treatment may have a particularly acute effect on establishing the viral reservoir in the brain.

Join us for more on each of these findings. To beat HIV, you have to follow the science!

Image Credit: Wavebreakmedia Ltd via Thinkstock

In our latest brief set of recaps from the world of recently published HIV research, we learn about studies that suggest:

  • Polypharmacy doesn't appear much riskier for people with HIV than people without -- but it's still a health risk factor, and an awfully common one at that.
  • In certain cases, PrEP use may well be associated with higher sexually transmitted infection incidence among MSM.
  • Particular species of vaginal bacteria may be associated with a greater risk of HIV seroconversion following a viral exposure.
  • Early initiation of HIV treatment may have a particularly acute effect on establishing the viral reservoir in the brain.

Join us for more on each of these findings. To beat HIV, you have to follow the science!

Image Credit: Wavebreakmedia Ltd via Thinkstock